Dulaglutide for erectile dysfunction in type 2 diabetes
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Lancet Diabetes and Endocrinology |
Vol/bind | 9 |
Udgave nummer | 8 |
Sider (fra-til) | 472-473 |
Antal sider | 2 |
ISSN | 2213-8587 |
DOI |
|
Status | Udgivet - aug. 2021 |
Bibliografisk note
Funding Information:
SM is on advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sanofi, and Bayer, receives speaker fees from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, and Sanofi, and has received research grants from Novo Nordisk and Boehringer Ingelheim.
ID: 285950615